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Abstract
Background: The HIV-1 envelope glycoprotein gp120, which mediates viral attachment to target cells,
consists for ~50% of sugar, but the role of the individual sugar chains in various aspects of gp120 folding
and function is poorly understood. Here we studied the role of the carbohydrate at position 386. We
identified a virus variant that had lost the 386 glycan in an evolution study of a mutant virus lacking the
disulfide bond at the base of the V4 domain.
Results: The 386 carbohydrate was not essential for folding of wt gp120. However, its removal improved
folding of a gp120 variant lacking the 385–418 disulfide bond, suggesting that it plays an auxiliary role in
protein folding in the presence of this disulfide bond. The 386 carbohydrate was not critical for gp120
binding to dendritic cells (DC) and DC-mediated HIV-1 transmission to T cells. In accordance with
previous reports, we found that N386 was involved in binding of the mannose-dependent neutralizing
antibody 2G12. Interestingly, in the presence of specific substitutions elsewhere in gp120, removal of N386
did not result in abrogation of 2G12 binding, implying that the contribution of N386 is context dependent.
Neutralization by soluble CD4 and the neutralizing CD4 binding site (CD4BS) antibody b12 was
significantly enhanced in the absence of the 386 sugar, indicating that this glycan protects the CD4BS
against antibodies.
Conclusion: The carbohydrate at position 386 is not essential for protein folding and function, but is
involved in the protection of the CD4BS from antibodies. Removal of this sugar in the context of trimeric
Env immunogens may therefore improve the elicitation of neutralizing CD4BS antibodies.
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Background
The HIV-1 envelope (Env) glycoproteins (gp120 and
gp41) mediate viral entry into target cells by binding to
the appropriate cellular receptors and facilitating fusion of
viral and cellular membranes. The ectodomain of the Env
complex is composed for ~50% of carbohydrates that
have multiple functions. i) Proper folding of Env in the
Endoplasmic Reticulum (ER) is dependent on glycosyla-
tion and Env misfolding occurs in the presence of glyco-
sylation inhibitors [1-3]. ii) Carbohydrate moieties are
important for HIV-1 binding to C-type lectins on den-
dritic cells (DCs), such as DC-SIGN, which have been
implicated in early viral transmission events and dissemi-
nation to CD4+ T cells [4-6]. iii) Env carbohydrates pro-
vide evasion from humoral immune responses through
shielding of important protein epitopes from antibodies
[7,8]. On rare occasions the carbohydrates on Env can
induce rather than shield from neutralizing antibodies [9-
12]. iv) Gp120-associated carbohydrates are involved in
an additional means of immune evasion: the induction of
immunosuppressive responses through the same interac-
tions with C-type lectins as used by the virus during dis-
semination [13]. v) Gp120 glycosylation, in particular the
glycosylation site within the V3 region, is involved in co-
receptor use [14,15]. Collectively, alterations in gp120
Env glycosylation patterns affect several viral properties,
including protein folding, (co)receptor usage, the induc-
tion of immune responses and escape from effective
immune responses.
The role of individual gp120 glycans in protein structure
and function is poorly understood. It is unclear which par-
ticular carbohydrates are involved in folding, C-type lectin
binding, and immune evasion. A precise delineation of
which sugars are important for what function is difficult
because of the variation in number and location of glyco-
sylation sites and the heterogeneous composition of the
individual sugar chains. Furthermore, carbohydrates may
serve different roles and multiple carbohydrates can col-
lectively serve a single function.
In this study we have focused on one particular Env carbo-
hydrate and investigated its role in various aspects of virus
phenotype. We observed that the 386 glycan, at the base
of the V4 domain, is not critical for Env folding, but its
removal improved folding of an Env variant lacking the
neighboring 385–418 disulfide bond, suggesting that the
386 glycan may have an auxiliary role in the presence of
this disulfide bond. The 386 glycan was not essential for
DC-binding and DC-mediated transmission. In contrast,
the 386 carbohydrate had a major impact on neutraliza-
tion sensitivity. Elimination of the 386 glycan resulted in
resistance to the 2G12 antibody, but surprisingly, the con-
tribution of this glycan appeared to be context dependent.
Interestingly, all viruses lacking the 386 glycan were
extremely sensitive to neutralization by the CD4BS anti-
body b12, suggesting that this sugar plays a role in protect-
ing the CD4BS from antibodies.
Results
Evolution of a folding defective gp120
In a previous study we found that elimination of the
disulfide bond at the base of V4 loop (C385–C418; fig.
1A) strongly impaired oxidative folding of HIV-1 Env
[16]. However, we reproducibly observed a low level of
infectivity of mutant viruses lacking this disulfide bond,
although not sufficient to cause a spreading infection. A
minority of the Env molecules apparently did exit the ER
and reach the cell and/or virion surfaces to mediate
attachment and membrane fusion. This phenotype quali-
fied for forced protein evolution studies, with the aim of
identifying and investigating escape routes that result in
restoration of gp120 folding and virus replication in the
absence of this particular disulfide bond. Here we describe
the evolution of revertants from the C418A single mutant.
We performed multiple independent evolution experi-
ments by transfecting the molecular clone of the HIV-1LAI
C418A virus into SupT1 T cells followed by long-term cul-
turing and passaging of the virus. Population sequencing
revealed the sequential appearance of two amino acid
substitutions: N386D and A433T (revertant R1, fig. 1B
&1C). Sequencing of individual env clones revealed that
several contained the individual N386D reversion alone,
implying that this mutation appeared first during the
course of evolution (fig. 1B). The N386D substitution dis-
rupted an N-linked glycosylation motif (NST386-388; gly-
cosylation site underlined) and thus led to the
elimination of the oligomannose glycan that otherwise
would be attached to N386 [17]. Note that this residue is
located immediately adjacent to C385, the partner of
C418 in the wt protein.
In an independent evolution culture we observed the
elimination of a neighboring glycan at position 392 by
deletion of the duplicate motif FNSTW (residues 391–395
or 396–400; revertant R2; fig 1B &1C). In addition, we
found a substitution at position 436 (A436T) and some
substitutions outside the V4-C4 domain (T188N, N230D,
A316T, N339Y, R696K). Two of these distal changes cause
the elimination of another carbohydrate (N230D,
N339Y), while a third causes a putative shift of a glyco-
sylation site by two residues (T188N; NDTTS to NDNTS;
residue 188 in bold).
The defect of the C418A virus may be caused by the
absence of the C385–C418 disulfide bond or the presence
of a free cysteine at position 385. The unpaired cysteine at
position 385 was not eliminated by the virus, suggesting
that the free cysteine is not a major problem or that it isRetrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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Local reversions in HIV-1 gp120 Figure 1
Local reversions in HIV-1 gp120. A. Schematic of gp120 with the 5 conserved domains (C1–C5 and five variable domains (V1–V5). The location of the V4 
base disulfide bond is indicated (grey sphere). The figure is adapted from [17] and sites for N-linked glycosylation are shown. B. Local reversions after evo-
lution. A detailed description of the evolution is given in materials and methods section. Sequences of the V4 loop and flanking regions of wt, mutant and 
revertant viruses. The original C418A mutation is indicated with a grey box, the reversions with black boxes. The sequences of revertant 1 are from day 
39 after transfection (both 1a and 1b were derived from the day 39 sample). The sequences of revertant 2 are from day 77 (2a) and day 136 (2b) after 
transfection. Revertant 2 also contained reversions outside the indicated domain: T188N, N230D and R696K at day 77, and A316T, N339Y in addition to 
these at day 136. C. Locations of the reverted residues on the 3D structure of gp120. Ribbon diagram of the crystallized core of gp120 [53] with residue 
418 in yellow and the reversions in red. Note that several reversions in R2 are not indicated because they are located outside the crystallized core (resi-
dues 188 and 316 (located in the V2 and V3, respectively), and residue 696 in gp41).
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compensated for by one or more of the acquired substitu-
tions. We also did not observe restoration of the disulfide
bond by means of a first site reversion at position 418.
This is probably due to the high mutational threshold to
convert the introduced alanine codon back into a cysteine
codon, which would require at least two nucleotide
changes. In fact, we designed the mutant such that rever-
sion to the wt cysteines was unlikely to occur, and thus to
favor evolution of interesting second-site reversions. In
summary, in two independent evolution experiments ini-
tiated with the C418A virus, a nearby carbohydrate was
eliminated (R1: N386; R2: N392). Considering the impor-
tance of carbohydrates in folding, the proximity of the
N386 sugar to the eliminated 385–418 disulfide bond
and proximity to the CD4BS we decided to focus our sub-
sequent experiments on R1 and the N386D substitution.
Improvement of virus replication
To establish that the substitutions we identified in R1
accounted for the revertant phenotype, the relevant env
fragments were recloned into the HIV-1LAI (pLAI) molecu-
lar clone. Virus stocks were produced and target cells were
infected with wt, mutant (mut: C418A) and revertant (R1a:
N386D C418A, R1b: N386D C418A A433T) viruses. Sub-
sequent virus spread was monitored by CA-p24 ELISA
(fig. 2A). As previously described, mut did not cause a
spreading infection [16]. R1a showed partial restoration
of virus replication, which was further improved by the
subsequent acquisition of the A433T substitution in R1b
resulted in a further improvement of virus replication.
These results indicate that a two-step evolution process
took place upon removal of the 418 cysteine and, hence,
the 385–418 disulfide bond, with both reversions con-
tributing to the final revertant phenotype.
To obtain more insight in the role of the various substitu-
tions in the restoration of virus replication, we con-
structed for comparison the C418A A433T double
mutant. This mutant did not appear during the evolution
experiment but did replicate quite efficiently, albeit with
delayed kinetics compared to wt. We constructed the
N386D single mutant to investigate the effect of this sub-
stitution and the loss of local carbohydrate on protein
folding and virus phenotype. Thus, while the N386D sub-
stitution improves virus replication in the context of the
C418A mutation (R1a), it does not appear to have a major
impact on the wt virus.
Restoration of gp120 content of virus particles
We previously found that folding-defective Env mutants
yield virions containing virtually no Env molecules
because the majority of Env is retained in the ER [16]. We
studied the contribution of the N386D substitution on
the relative content of Env molecules on virions,
expressed as the gp120/CA-p24 ratio (fig. 2B). The gp120/
CA-p24 ratio for wt virions was arbitrarily set at 100%. As
anticipated, mut accumulated gp120 in the cell fraction
(not shown), and very little gp120 (10.4%) was found on
virus particles (fig. 2B). This result is consistent with the
severe folding defect measured for this mutant. The addi-
tion of the N386D substitution in R1a resulted in a mod-
est but reproducible restoration of gp120 virion content
to 16.2%, suggesting that protein folding was improved
by the N386D substitution. The N386D substitution
caused a slightly lower gp120 content (90.2%) in the
Reversions improve viral replication Figure 2
Reversions improve viral replication. A. 50 × 103SupT1 T cells were infected with 2500 pg CA-p24 and virus spread was measured for 14 days. B. gp120 
and CA-p24 contents in virus were measured by ELISA. The gp120 amounts were standardized for CA-p24 input and the gp120 contents of mutants in the 
respective fractions are given as percentages of the wt gp120 contents (arbitrarily set at 100). The results are representative for results from at least three 
independent experiments.
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absence of C418A, indicating the improvement is specific
for the C418A context.
Partial restoration of oxidative folding
To study whether improved protein folding of the rever-
tants accounted for the increase in gp120 incorporation
into virions, we monitored Env maturation by pulse-chase
analysis. Folding of the gp120 subunit alone is very simi-
lar to that of the gp160 precursor [18]. We therefore
expressed the variant gp120 molecules in HeLa cells, radi-
olabeled the cells and analyzed detergent cell lysates and
culture supernatants for presence and folding state of
gp120. We compared maturation kinetics using three
read-outs that we developed before (fig. 3)[18]. First, we
analyzed the formation of disulfide bonds by following
mobility changes of cellular gp120 in non-reducing SDS-
PAGE. Second, we monitored signal peptide cleavage in
reducing SDS-PAGE. Third, we measured secretion of
gp120 into the culture supernatant by reducing SDS-
PAGE.
At 0 hr, all gp120 variants displayed the same mobility in
the nonreducing gel, indicating that, directly after the
pulse, few if any disulfide bonds had formed (fig. 3). After
2 hrs of chase, wt gp120 migrated faster in the non-reduc-
ing gel indicating the formation of the fully oxidized
native state (NT). In contrast, most gp120 molecules of
the mutant and revertants appeared as rather unfolded
protein, while a minority was present as a faster migrating
'smear', representing various species of partially oxidized
folding intermediates (IT). Mut did not display detectable
levels of the native state even after 4 hrs. The revertants,
however, did in part reach the native state. R1a and R1b
displayed a faint native band after 2 hrs of chase.
An unusual property of Env is that it must undergo some
initial oxidative folding before its signal peptide can be
removed [18]. Signal peptide cleavage therefore can be
used as a measure for proper gp120 folding. In reducing
gels, only a single band corresponding with the preprotein
form of gp120 (Reduced uncleaved = Ru) was present
directly after the pulse (fig. 3). After 2 hrs of chase, how-
ever, a prominent band just below the reduced band
appeared, corresponding to gp120 from which the signal
peptide had been cleaved off (Reduced cleaved = Rc). After
4 hrs of chase, no uncleaved species were detectable any
Reversions partially restore gp120 folding Figure 3
Reversions partially restore gp120 folding. HeLa cells were infected with VVT7 and transfected with plasmids encoding mutant and revertant or wt gp120. 
Cells were pulse-labeled for 5 min. and chased for the indicated times. Cells were lysed and gp120 was immunoprecipitated from lysates. Immunoprecipi-
tates were deglycosylated with endoH and analyzed by either reducing or nonreducing 7.5% SDS-PAGE. Folding intermediates (ITs), the native form (NT), 
the reduced state from which the signal peptide was cleaved off (Rc) or not (Ru) are indicated. In addition, secreted gp120 was immunoprecipitated from 
the culture supernatant after 8 hr chase and directly analyzed by reducing SDS-PAGE.
A   = C418A (mut)
D   = N386D
DA  = N386D C418A (R1a)
AT  = C418A A433T
DAT = N386D C418A A433T (R1b)
ITs
NT Rc
RuRetrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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longer for wt. Signal peptide cleavage was significantly
reduced for mut, but the R1a and R1b gp120 molecules
showed partially restored cleavage, although complete
processing was not accomplished. The third read-out con-
firmed the partial restoration of productive folding.
Unlike mut gp120, a fraction of the revertant gp120 mol-
ecules was secreted after 8 hrs (fig. 3). Secreted wt gp120
appeared as compact bands, but secreted R1a and R1b
gp120 displayed a smear, which may be a consequence of
slower folding kinetics as prolonged retention in the ER
may lead to excessive mannose trimming, resulting in
more heterogeneous glycan structures [19,20]. Alterna-
tively, a different conformation may lead to different
accessibility of the carbohydrates and result in different
processing. Combined, these results are consistent with
the Env incorporation and virus replication experiments
and confirm that virus-driven evolution resulted in a par-
tial repair of gp120 folding by means of the N386D and
A433T substitutions. In all three read-outs, the N386D
single mutant was indistinguishable from wt, implying
that the glycan at position 386 does not play an important
role in wt gp120 folding.
Inhibition by soluble CD4 and AMD3100
To assess the conformation and function of the mutant
and revertant Env proteins on virus particles, we studied
the sensitivity of the revertant viruses to inhibitors of viral
entry in a PBMC-based neutralization assay (fig. 4). The
location of the binding sites of the receptor, CD4, and the
CXCR4 coreceptor for HIV-1LAI in relation to the positions
of the mutations and reversions in our viruses is given in
fig. 4A. Soluble CD4 (sCD4) was used to assess the inter-
action of these viruses with CD4. The wt virus was neutral-
ized by sCD4 with an IC50 of ~16 μg/ml. The various
viruses (except mut, which did not replicate in PBMCs),
were neutralized efficiently at lower concentrations of
sCD4 (IC50 of ~1–8 μg/ml) suggesting that the affinity for
CD4 is increased in these variants. R1b was the most sen-
sitive to neutralization by sCD4 (IC50 of ~1.0 μg/ml).
As a measure for the affinity of Env for the co-receptor,
which is CXCR4 in case of the HIV-1LAI strain, we investi-
gated the sensitivity of the same panel of viruses to
AMD3100, a small molecule inhibitor of CXCR4 (fig. 4).
The wt virus was inhibited by AMD3100 with an IC50 of
~0.7 μg/ml. R1a was inhibited at similar concentrations,
while the other virus variants were more sensitive to
AMD3100 (R1b, N386D, C418A A433T: IC50 of ~0.1–0.3
μg/ml). Again R1b was the most sensitive (IC50 of ~0.1 μg/
ml). The observation that less inhibitor was necessary to
inhibit the interaction of these viruses with CXCR4 sug-
gested that the affinity for CXCR4 was decreased. Taken
together, the revertant R1b displayed increased affinity for
the receptor (CD4) and decreased affinity for the co-recep-
tor (CXCR4).
Neutralization by antibodies b12 and 2G12
We next studied the interaction of the various viruses with
the neutralizing monoclonal antibodies b12 and 2G12.
The broadly neutralizing antibody b12 is directed to the
CD4BS and the reversions are close to its epitope (fig. 5A)
[21]. Wt virus was inhibited with an IC50 of ~20 μg/ml
(fig. 5B). The C418A A433T mutant was similarly inhib-
ited. Strikingly, all the mutants and revertants containing
the N386D substitution (R1a, R1b and the N386D single
mutant) were at least 10-fold more sensitive to b12 neu-
tralization (IC50 of ~1.5 μg/ml), suggesting that this sub-
stitution caused an increased b12 binding.
Broadly neutralizing antibody 2G12 is directed to a
number of oligomannose glycans on the outer face of
gp120 (fig. 5A; [10,11]). While probably not part of the
epitope itself, the carbohydrate at N386 is involved in
proper formation and/or presentation of the epitope
[10,11]. The wt virus was very sensitive to neutralization
by 2G12 and the C418A A433T double mutant was
slightly more resistant (IC50 of ~0.05 and ~4.0 μg/ml; fig.
5B). The N386D and R1a mutants were completely resist-
ant at the concentrations tested, in line with studies
implying the indirect involvement of the 386 glycan in
2G12 binding [10-12]. Strikingly, R1b, which also lacks
the 386 glycan, was sensitive to 2G12 neutralization.
Effect of the N386D substitution on neutralization
To further characterize the contribution of N386 to neu-
tralization and to corroborate the data obtained in the
PBMC-based neutralization experiments, we performed
single cycle neutralization experiments using complete
HIV-1LAI virus (fig. 6 and table 1). We also included pseu-
dovirus of the CCR5-using HIV-1JR-FL strain. As in the
PBMC-based assay, the N386D mutant was completely
resistant to 2G12 neutralization while the wt virus was
sensitive (IC50 of >10 μg/ml and 1.93 μg/ml, respectively;
fig. 6 and table 1). Similar results were obtained using the
HIV-1JR-FL strain, but the HIV-1JR-FL N386D variant was not
as resistant to 2G12 neutralization as the HIV-1LAI variant
(IC50s of 0.66 μg/ml (wt) and 7.96 μg/ml (N386D)), con-
firming that the involvement of the 386 glycan to the
2G12 epitope is variable and/or context dependent.
We next tested the accessibility of the CD4BS. The HIV-
1LAI N386D variant was approximately 3-fold more sensi-
tive to CD4-IgG2 neutralization compared to wt (IC50 of
0.28 μg/ml and 0.78 μg/ml, respectively), mimicking the
results obtained in the PBMC-based neutralization exper-
iments using sCD4. Similar results were obtained using
HIV-1JR-FL pseudovirus, although the difference in IC50
was less than 2-fold (0.11 μg/ml versus 0.17 μg/ml). Both
wt (pseudo)viruses were sensitive to b12 neutralization,
but the N386D variants were much more sensitive (8-fold
for HIV-1LAI and 2-fold for HIV-1JR-FL). Apparently the roleRetrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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Inhibition by inhibitors of receptor interactions Figure 4
Inhibition by inhibitors of receptor interactions. A. Locations of mutations and reversions on the structure of gp120 relative to 
the receptors binding sites. In this orientation the cell membrane would be on top, the viral membrane below and allows a 
direct view on the CD4BS. The lower panels show a 90° rotated view, a view from the target membrane. Residue 418 is indi-
cated in yellow, and residues 386 and 433 are indicated in red. The GlcNac2Man3 core pentose of the carbohydrate attached 
to N386 is indicated in cyan (modeled onto gp120 by Dr. Peter Kwong). The residues important for the interaction with CD4 
and the coreceptor are indicated in blue and green, respectively. B. Inhibition of virus variants with sCD4 and AMD3100 on 
CD4+ enriched lymphocytes. Inhibition curves are depicted for each of the viruses in limiting dilutions of either sCD4 (left 
panel) or the CXCR4 inhibitor AMD3100 (right panel).
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of N386 in protection of the CD4BS is less pronounced in
HIV-1JR-FL Env. Monoclonal antibody b6 is derived from
the same phage library as b12 [22], however, it does not
neutralize very efficiently, presumably because its angle of
binding to gp120 is incompatible with binding to the Env
trimer [23]. We indeed observed that wt HIV-1LAI and wt
HIV-1JR-FL were both resistant to b6 neutralization. Fur-
thermore, the N386D substitution did not increase the
sensitivity of these viruses to b6. These data indicate the
N386D specifically increases exposure of the neutralizing
b12 epitope on the functional Env trimer, but not of the
nonneutralizing b6 epitope. This is in contrast to HIV-1LAI
viruses lacking the V1/V2 domain which show increased
sensitivity to both b12 and b6 (R.W. Sanders et al. unpub-
lished results). Allthough these data should be extended
by testing other nonneutralizing CD4BS antibodies, the
specific improvement of exposure of the b12 epitope may
be relevant to vaccine design aimed at inducing b12-like
antibodies, while avoiding the elicitation of nonneutraliz-
ing antibodies.
Inhibition by neutralizing antibodies Figure 5
Inhibition by neutralizing antibodies. A. Locations of mutation and reversions on the structure of gp120 relative to the epitopes for neutralizing antibodies 
b12 and 2G12. Colors are the same as in fig. 4A. Residues important for b12 binding [23] are indicated in blue and the asparagines which anchor the gly-
cans involved in 2G12 binding [10-12] are indicated in magenta. B. Neutralization of the virus variants with selected monoclonal antibodies on CD4+ 
enriched lymphocytes. Neutralization curves are depicted for the various viruses in limiting dilutions of the b12 (top panel) and 2G12 (bottom panel) anti-
bodies.
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Table 1: Neutralization in single cycle assays (50% inhibitory 
concentrations (μg/ml))a
LAI (whole virus) JR-FL (pseudovirus)
wt N386D wt N386D
2G12 1.93 >10 0.66 7.96
CD4-IgG2 0.78 0.28 0.17 0.11
b12 0.62 0.079 0.043 0.020
b6 >10 >10 >10 >10
a The IC50 values were derived from the experiment in fig. 6 as 
described in the materials and methods section.Retrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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DC binding and transmission
Because oligomannose containing carbohydrates on
gp120 interact with C-type lectins on dendritic cells (DC)
and facilitate DC-mediated transmission to T cells [4-6],
we examined whether the N386 glycan, which is thought
to exist as an oligomannose carbohydrate on gp120 [17],
contributed to binding of HIV-1 to DC. First, we deter-
mined the infectivity of both wt and N386D HIV-1LAI in a
single-cycle infection assay using LuSIV reporter cells.
These reporter cells contain the firefly luciferase gene
downstream of the LTR promoter, resulting in Tat-medi-
ated luciferase expression, which is a measure of infectiv-
ity [24]. In accordance with the replication experiments,
we found no significant differences (fig. 7A). We next
incubated DC with both viruses for 2 hrs, followed by
washing steps to remove unbound virus. After lysis of the
cells, we measured the amount of captured HIV by CA-
p24 ELISA and found no significant difference in wt or
N386D virus capture by DC (fig. 7A). These results show
that the N386 glycan is not essential for binding to DC.
Finally, we tested whether wt or N386D virus was trans-
mitted with equal efficiency by DC to T cells. DC were
The N386 carbohydrate is not essential for DC-mediated HIV-1 transmission Figure 7
The N386 carbohydrate is not essential for DC-mediated HIV-1 transmission. A. LuSIV cells were incubated with the two viruses and luciferase was meas-
ured after 24 hours. RLU, relative light units. Error bars represent standard deviations. B. DCs were incubated for 2 hours with wt or N386D virus, fol-
lowed by extensive washing to remove unbound virus. Viral capture was subsequently determined by lysis of the cells and CA-p24 ELISA. C. DCs were 
incubated for 2 hours with wt or N386D virus, followed by extensive washing to remove unbound virus. DCs were subsequently cocultured with LuSIV 
cells to allow HIV-1 transmission. Transmission efficiency was determined by measuring luciferase activity after 24 hours.
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Neutralization in single cycle infection assays Figure 6
Neutralization in single cycle infection assays. Wt an d N386D HIV-1LAI virus and wt and N386D pseudovirus derived from HIV-1JR-FL were preincubated 
with antibody and subsequently incubated with TZM-bl cells containing a luciferase reporter construct under control of the HIV-1 LTR as described in the 
materials and methods section. The luciferase activity in the absence of inhibiting reagents was set at 100%.
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incubated with virus for 2 hrs, followed by washing steps
and addition of LuSIV cells. Since the LuSIV cells are har-
vested within 24 hrs for luciferase measurement, there is
no significant T cell spread of newly produced HIV-1 viri-
ons, such that luciferase activity is a quantitative measure
of the amount of virus that is transmitted by DC. We
found no significant differences in transmission efficiency
(fig. 7C), which was expected since both capture by DC
and infectivity of N386D was similar to wt HIV-1 (figs. 7A
and 7B). Since HIV-1 binding to monocyte-derived DC
predominantly takes place via C-type lectins such as DC-
SIGN [6,25-27], these results imply that the individual
386 carbohydrate is not essential for C-type lectin binding
and DC-mediated transmission.
Discussion
The carbohydrate component of Env, comprising ~50% of
its molecular weight, is much less well characterized than
the protein component. The sugars facilitate different
functions and display an unusual plasticity in terms of
composition, structure and location. Thus, sugar chains
can move around the molecule, they are flexible and their
composition depends on the local environment. Further-
more, the carbohydrates on Env can serve many purposes.
This study on the 386 carbohydrate underlines some of
these features.
The N386D substitution does not appreciably affect oxi-
dative folding of gp120, but it does improve folding of a
gp120 variant lacking the 385–418 disulfide bond caused
by the C418A substitution. Perhaps the 386 sugar has a
supporting role in folding of wt gp120 that was not appar-
ent in our assays, but may be more prominent in (resting)
primary immune cells, which may enforce more con-
straints on protein folding than transformed cell lines. We
observed the loss of a nearby glycan in two independent
evolution experiments using the C418A single mutant.
The carbohydrates at positions 386 and 392 were not lost
in evolution studies using the C385A C418A double
mutant [16]. It is therefore possible that the loss of local
carbohydrate somehow compensates for the presence of
an unpaired cysteine at position 385.
Although the 386 glycan exists as an oligomannose carbo-
hydrate that could potentially bind to DC-SIGN and/or
other lectins on DC [17], our DC transmission studies
suggest that N386 is not essential for gp120 binding to
DC. However, recent studies show that although the bind-
ing of DC-SIGN to gp120 has some specificity it is also
considerably promiscuous [28]. It remains possible that
N386 plays a facilitating role in binding to DC-SIGN and/
or other lectins in vivo, in combination with other carbo-
hydrates on gp120. A better definition of the binding
domain(s) for lectins such as DC-SIGN on gp120 is war-
ranted.
The 386 carbohydrate was previously found to be
involved in 2G12 binding, such that it facilitates the
proper formation or presentation of the 2G12 mannose
epitope [10,11]. Although not directly part of the 2G12
epitope, the removal of N386 may result in different mod-
ification of the neighbouring sugars that form the core
epitope. 2G12 requires terminal mannose residues on oli-
gomannose chains. The removal of the 386 sugar may
result in enhanced accessibility of the sugars that normally
bind 2G12, resulting in processing of the oligomannose
chains to complex carbohydrate and consequently a loss
of terminal mannose residues. Our findings confirm these
results, but also show that the contribution of the 386 car-
bohydrate is context dependent. Thus, in the presence of
the C418A and A433T mutations the 386 sugar is not crit-
ical for formation or presentation of the 2G12 epitope.
Apparently, these mutations result in decreased accessibil-
ity of the 2G12 carbohydrates even in the absence of the
386 sugar.
Much effort is put into attempts to elicit antibodies simi-
lar to the few broadly neutralizing antibodies that have
been isolated and characterized (b12, 2G12, 4E10, 2F5).
The b12 epitope/CD4BS is an attractive target since most,
if not all, primary HIV-1 viruses need CD4 for entry. We
show here that the removal of the 386 glycan significantly
improves b12 and CD4 binding to virus-associated Env. A
recent study showed that a N386Q substitution in a pri-
mary subtype C isolate also significantly enhanced the
sensitivity to b12 neutralization, strengthening the notion
that the 386 carbohydrate hides the b12 epitope [29].
Similar results were obtained with an N386A substitution
in JR-FL (R. Pantophlet and D. Burton, personal commu-
nication). These data also indicate that it is probably not
the chemical property of the introduced amino acid that
causes the increased sensitivity, but rather the lack of the
carbohydrate. Interestingly, both the asparagine at posi-
tion 386 and the attached glycan are contact sites for b12
on monomeric gp120 [30], but apparently, in the context
of the functional trimer, the 386 glycan located on the
edge of gp120's silent face shields the CD4BS and the b12
epitope [7].
Since the 386 carbohydrate is involved in protection of
the CD4BS from antibodies it may be worthwhile to con-
sider the elimination of this carbohydrate in Env-based
immunogens. Several studies demonstrated a benefit
from the reduction of carbohydrates in terms of the expo-
sure of the CD4BS and the induction of neutralizing anti-
bodies, although other studies did not show such an effect
[31-39]. However, systematic studies analyzing the contri-
bution of every single carbohydrate are lacking. Further-
more, the antigen scaffold used in these studies (virus-
associated Env, monomeric gp120 and incompletely
cleaved or uncleaved gp140/gp150/gp160) may not beRetrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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optimal for such an analysis. The contribution of sugar
chains to protection from antibody recognition may be
quite different in the context of a better mimic of the func-
tional trimer [7].
Conclusion
Although the 386 carbohydrate may play a role in Env
folding, this is not a crucial one, underlined by the fact
that it is not absolutely conserved among primary isolates
(15% variability in clades A, B, and C [10]). Despite the
observation that this sugar is present as an oligomannose
carbohydrate [17], it does not seem to play an essential
role in the binding to DC and DC-mediated transmission.
As previously reported, the 386 sugar contributes to 2G12
binding, but we show here that this contribution is not
direct. The main finding of our study is that the glycan at
residue 386 plays a role in the protection of the CD4BS
against antibody recognition. Although antigenicity can-
not be directly correlated with immunogenicity, removal
of the 386 glycan in trimeric Env vaccines may facilitate
elicitation of neutralizing b12-like CD4BS antibodies.
Studies to test this hypothesis are in progress.
Methods
Cloning
The pRS1, pcDNA3-Env-gp120 and pLAI plasmids con-
taining the appropriate mutations in the env gene were
generated as described previously [16]. PCR-generated
gp120 sequences from evolved viruses (see below) were
cloned into the pRS1 shuttle vector [40] using the BsaB1
and Nhe1 sites and subsequently cloned into the pLAI
infectious molecular clone [41] as SalI-BamHI fragments.
NotI-XhoI fragments were subcloned into the pcDNA3
expression vector for use in folding experiments. Number-
ing of individual amino acids is based on the sequence of
HXB2 gp160.
Cells and transfections
HeLa cells (ATCC) and HT1080 cells were cultured in
MEM (Life technologies) supplemented with 10% FCS
(Hybond), penicillin (100 U/ml; Sigma-Aldrich), strepto-
mycin (100 μg/ml; Invitrogen). SupT1 cells were cultured
in RPMI medium 1640 (Life Technologies) supplemented
with 10% FCS, penicillin and streptomycin. C33A cervix
carcinoma cells were maintained in DMEM (Life Technol-
ogies), supplemented with 10% FCS, penicillin and strep-
tomycin, as previously described [42]. SupT1 and C33A
cells were transfected with pLAI by electroporation and
Ca3(PO4)2 precipitation, respectively, as described previ-
ously [43]. The reporter cell line LuSIV was kindly
donated by Janice E. Clements (Johns Hopkins University
School of Medicine, Baltimore, MD). This CEMx174-
derived cell line contains the firefly luciferase reporter
gene downstream of the SIVmac239 LTR. Infection by HIV-
1 results in Tat-mediated expression of luciferase, which
can be measured 24 hours later. Cells were maintained in
RPMI medium, supplemented with 10% FCS, 2 mM
sodium pyruvate, 10 mM HEPES, 2 mM L-glutamine, pen-
icillin (100 U/ml), streptomycin (100 μg/ml), and hygro-
mycin B (300 μg/ml) to maintain the luciferase construct.
For experiments with DCs, hygromycin B-free medium
was used. Peripheral blood mononuclear cells (PBMCs
were isolated from fresh buffy coats (Central Laboratory
Blood Bank, Amsterdam) by standard Ficoll-Hypaque
density centrifugation. PBMCs were frozen in multiple
vials at a high concentration and, when required, thawed
and activated with 5 μg/ml phytohemagglutinin (Sigma)
and cultured in RPMI medium containing 10% FCS, pen-
icillin (100 U/ml), streptomycin (100 μg/ml), and recom-
binant interleukin-2 (rIL-2) (100 units/ml). On day 4 of
culture, the cells underwent CD4+ enrichment by incubat-
ing the PBMC with CD8 immunomagnetic beads (Dynal)
and separating out the CD8+ lymphocytes.
Viruses and infections
Virus stocks were produced by transfecting C33A cells
with the appropriate pLAI constructs. The virus containing
supernatant was harvested 3 days post-transfection, fil-
tered and stored at -80°C and the virus concentration was
quantitated by capsid CA-p24 ELISA as described previ-
ously [44]. These values were used to normalize the
amount of virus in subsequent infection experiments.
Infection experiments were performed as follows. 50 ×
103 SupT1 T cells were infected with 2500 pg CA-p24 of
C33A-produced HIV-1LAI per well in a 96-well plate, and
virus spread was measured for 14 days using CA-p24
ELISA. For single-cycle experiments to determine viral
infectivity, 40 × 103 LuSIV cells/200 μl/well were infected
virus (2 ng CA-p24/well), followed by luciferase measure-
ment after 24 hrs, as described previously [45]. JR-FL
pseudoviruses were produced by cotransfection of 3.3 μg
pSV7D-JR-FL gp160 (a gift from James Binley) and 1,7 μg
pSG3-ΔEnv (obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH from Drs. John C. Kappes and Xiaoyun Wu) into
293T cells.
Virus evolution
Evolution experiments were essentially performed as pre-
viously described [40,46]. 5 × 106 SupT1 cells were trans-
fected with 10 μg of the pLAI C385A/C418A construct by
electroporation. The culture was inspected regularly for
the emergence of revertant viruses, using CA-p24 ELISA
and/or the appearance of syncytia as indicators of virus
replication. Cells were passaged twice a week. Decreasing
amounts (1.0 ml, 100 μl, 10 μl, 1.0 μl) of virus were pas-
saged cell free onto fresh cells when the cells were
(almost) wasted due to infection. The intervals and vol-
umes of cell free passage depended on the replication effi-
ciency and cytopathogenicity of the evolving virus. UponRetrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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identification of a faster replicating virus, DNA was
extracted from infected cells [47] and proviral gp120
sequences were PCR-amplified with primers A (5'-GCTC-
CATGGCTTAGGGCAACATATATCTATG-3') and B (5'-
GTCTCGAGATGCTGCTCC-3') and sequenced. Popula-
tion sequencing revealed two reversions: N386D and
A433T (fig. 1). Half of the individual env clones that were
sequenced contained these two substitutions. However,
half of the clones only had the individual N386D rever-
sion, implying that this mutation appeared first during
the course of evolution (fig. 1).
HIV-1 neutralization assay using primary CD4+ 
lymphocytes
Viruses were tested for their relative inhibition sensitivity
against increasing concentrations of either sCD4 (Immu-
noDiagnostics, Inc.) or the CXCR4 binding compound
AMD3100 (a generous gift from Dr D Schols). TCID50 val-
ues were determined on purified CD4+ lymphocytes iso-
lated from an individual who did not carry the Δ32CCR5
allele (CCR5+/+) screened for by standard PCR. CD4+-
enriched lymphocytes were plated at 2 × 105 cells/well in
96-well plates with 5-fold serial dilutions of the virus. The
cells were fed on day 7 with fresh media and scored on day
14 for p24 levels, with the number of positive wells being
used to identify the TCID50 value for each virus. Each virus
(100 TCID50 in 50 μl of the culture RPMI medium) was
mixed with an equal volume of serially diluted compound
for 1 hr at 37°C in flat-bottomed 96-well plates and all
neutralization reactions were performed in triplicate.
After 1 hour of incubation 2.0 × 105positively selected
CD4+ lymphocytes were added to each well in 100 μl of
culture media containing rIL-2. For each neutralization
experiment a positive control, virus incubated with cells
in the absence of inhibitory compound, and a negative
control, virus in the absence of cells, was included. The
negative control p24 concentration was subtracted from
all test results. HIV-1 specific p24 production was meas-
ured on day 7, 10 and 14 of culture. On these days half the
cell supernatant of each well was replaced with fresh
medium. The day chosen for calculating neutralizing
responses was based on the day the p24 value of the pos-
itive control well peaked and percentage neutralization
was calculated by determining the reduction in p24 pro-
duction in the presence of the agent compared to that for
the cultures with virus only.
Single cycle virus Neutralization
The TZM-bl reporter cell line [48,49] stably expresses high
levels of CD4 and HIV-1 co-receptors CCR5 and CXCR4
and contains the luciferase and β-galactosidase genes
under control of the HIV-1 LTR promoter. The TZM-bl cell
line was obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu
and Tranzyme Inc. One day prior to infection, TZM-bl
cells were plated on a 96-wells plate in DMEM medium
(Gibco) containing 10% fetal bovine serum, 1× MEM
(Gibco) and penicillin/streptomycin (both at 100 units/
ml) and incubated at 37°C with 5% CO2. A fixed amount
of HIV-1LAI virus produced in C33A cells (500 pg CA-p24)
or HIV-1JR-FL pseudovirus produced in 293T cells (500 pg
CA-p24) was pre-incubated for 30 min at room tempera-
ture with escalating concentrations of monoclonal anti-
bodies (2G12: obtained from Hermann Katinger through
the NIH AIDS Research and Reference Reagent Program;
b6 and b12: gifts from Dennis Burton) or CD4 (sCD4,
CD4-IgG2: gifts from William Olson, Progenics Pharma-
ceuticals). This mixture was added to the cells in the pres-
ence of 400 nM saquinavir (Roche) and 40 μg/ml DEAE
in a total volume of 200 μl. Two days post-infection the
medium was removed and cells were washed once with
PBS and lysed in Reporter Lysis buffer (Promega). Luci-
ferase activity was measured using the Luciferase Assay kit
(Promega) and a Glomax luminometer according to the
manufacturer's instructions (Turner BioSystems). All
infections were performed in duplicate and luciferase
measurements were also performed in duplicate. Unin-
fected cells were used to correct for background luciferase
activity. The infectivity of each mutant without inhibitor
was set at 100%. Non-linear regression curves were deter-
mined and IC50 values were calculated using Prism soft-
ware version 4.0c.
Generation of monocyte-derived dendritic cells
Monocyte-derived dendritic cells were genereated as pre-
viously described [42,45,50]. Peripheral blood mononu-
clear cells (PBMC) were isolated by density centrifugation
on Lymphoprep (Nycomed). Subsequently, PBMC were
layered on a Percoll gradient (Pharmacia) with three den-
sity layers (1.076, 1.059, and 1.045 g/ml). The light frac-
tion with predominantly monocytes was collected,
washed, and seeded in 24-well culture plates (Costar) at a
density of 5 × 105 cells per well. After 60 min at 37°C,
nonadherent cells were removed, and adherent cells were
cultured to obtain iDC in Iscove's modified Dulbecco's
medium (IMDM; Life Technologies Ltd.) with gentamicin
(86  μg/ml; Duchefa) and 10% fetal clone serum
(HyClone) and supplemented with GM-CSF (500 U/ml;
Schering-Plough) and IL-4 (250 U/ml; Strathmann Biotec
AG). At day 3, the culture medium with supplements was
refreshed. At day 6, maturation was induced by culturing
the cells with poly (I:C) (20 μg/ml; Sigma-Aldrich). After
two days, mature CD14- CD1b+ CD83+ DC were obtained.
All subsequent tests were performed after harvesting and
extensive washing of the cells to remove all factors.
DC-binding experiments
Fully matured DC were incubated in a 96-well-plate (40 ×
103 DC/100 μl/well) with virus (5 ng CA-p24/well) for 2Retrovirology 2008, 5:10 http://www.retrovirology.com/content/5/1/10
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hr at 37°C. After centrifugation at 400 × g, the DC were
washed with PBS to remove unbound virus. This step was
repeated twice and was followed by lysis of the cells and
CA-p24 ELISA to determine the amount of HIV-1 cap-
tured by the DC.
Single-cycle DC transmission assay
Fully matured DC were incubated in a 96-well-plate (40 ×
103 DC/100 μl/well) with virus (5 ng CA-p24/well) for 2
hr at 37°C. The DC were washed with PBS after centrifu-
gation at 400 × g to remove unbound virus. Washing was
repeated twice, followed by addition of 40 × 103 LuSIV
cells. After 24 hr, LuSIV cells were harvested for luciferase
measurement. 40 × 103 LuSIV cells grown without DC or
HIV-1 were used to obtain the background luciferase
value, which was subtracted from all data.
Quantitation of gp120 in virus fractions
C33A cells were transfected with 40 μg pLAI per T75 flask.
Medium was refreshed at day one post-transfection. The
culture supernatant was harvested at 3 days post-transfec-
tion, centrifuged and passed through a 0.45 μm filter to
remove residual cells and debris. Cells were resuspended
in 1.0 ml lysis buffer (50 mM Tris (pH 7.4) 10 mM EDTA,
100 mM NaCl, 1% SDS). Virus particles were pelleted by
ultracentrifugation (100,000 g for 45 min at 4°C) and
resuspended in 0.5 ml lysis buffer. The virus free superna-
tant, containing gp120 shed from the cell and virion sur-
face, was concentrated using Amicon centrifugal filter
units (Millipore) and SDS was added to a 1% final con-
centration.
Gp120 in cell, virion and supernatant fractions was meas-
ured as described previously [10,51], with minor modifi-
cations. ELISA plates were coated overnight with sheep
antibody D7324 (10 μg/ml; Aalto Bioreagents), directed
to the gp120 C5 region, in 0.1 M NaHCO3. After blocking
with 2% milk powder in Tris-buffered saline (TBS) for 30
min, gp120 was captured by incubation for 2 hr at room
temperature. Recombinant HIV-1LAI  gp120 (Progenics
Pharmaceuticals) was used as a reference. Unbound
gp120 was washed away with TBS and purified serum Ig
from an HIV-1 positive individual (HIVIg) was added for
1.5 hr in 2% milk, 20% sheep serum, 0.5% Tween-20.
HIVIg binding was detected with alkaline phosphatase
conjugated goat anti-human Fc (1:10,000, Jackson Immu-
noresearch) in 2% milk, 20% sheep serum, 0.5% Tween-
20. Detection of alkaline phosphatase activity was per-
formed using AMPAK reagents (DAKO). The measured
gp120 contents in cells, virus and supernatant were nor-
malized for CA-p24.
Env folding
For folding assays, mutant gp120 was expressed using a
recombinant Vaccinia virus vector system. Folding of
gp120 mutants was analyzed by pulse-chase labeling and
immunoprecipition with rabbit sera raised against gp160
from lysed cells and recognizing all forms of gp160, as
described [18]. Wt, mutant and revertant gp120 were
expressed in HeLa cells under control of the T7 promoter
using a recombinant Vaccinia virus vector system [52].
Cells were placed on ice directly after the pulse or after var-
ious chase times. Culture supernatants were collected and
cells were washed, incubated with iodoacetamide to block
free sulfhydryl groups and lysed. gp120 from cell lysates
and culture supernatants was immunoprecipitated and
treated with Endoglycosidase H to remove oligomannose
glycans. This results in deglycosylation of virtually all
intracellular gp120 since the contribution of EndoH-
resistant gp120 in the cell is negligible [18]. Formation of
disulfide bonds was assayed by SDS-PAGE mobility
changes of deglycosylated, alkylated, non-reduced sam-
ples. Reduced samples were used to follow signal
sequence cleavage.
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